Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said it has become a founding sponsor of the Women in Psychedelics Network (WIP), created to bring women in the psychedelic industry together to build a community based on education, support, growth, and experience.
Led by the company’s CEO Najla Guthrie, both Wellbeing and its subsidiary, KGK Science Inc. (KGK) are founding supporters of the WIP, which hopes to recruit healthcare representatives, scientists, and company leaders, as well as sponsorships from companies that may not be led by women but are supporters of the network.
In a statement, Guthrie, who has demonstrated a strong desire to mentor, lead, and be an advocate for psychedelic compounds as medicine for mental health said: “I am excited for WIP and the value that it is expected to bring to women and the industry."
READ: Wellbeing Digital Sciences names Dr Michael Ho as medical director of its MindScape ketamine clinic
Guthrie has played a major role in growing KGK into a leading North American contract research organization that provides high-quality clinical trials with a focus on emerging psychedelic industries, the mental healthcare company said.
A recognized global leader and coveted spokesperson in the nutraceutical trade, Guthrie has published over 50 peer-reviewed papers and has given multiple presentations at both national and international levels, Wellbeing noted. She is also lobbying for the advancement of policy changes in the supplement and cannabis industries.
“As a founder, I am honoured to lead a wonderful group that supports women and promotes growth within the psychedelic and research communities. Women in this industry have so much to offer, and I am optimistic that WIP will foster an open, educational and collaborative atmosphere for women all around the world in which to share and create,” Guthrie, who is also the president and CEO of KGK, added.
The goal of the Wellbeing management team is to improve mental health and create innovative solutions, she said, adding that WIP will assist the industry to achieve that objective.
Separately, the company also announced that it has issued 5,000,000 common shares to an arm’s length agent at a deemed price per share of $0.25 for the identification, negotiation, and strategic advice in respect of joint ventures, partnerships, and clinic acquisition opportunities. The shares are subject to a hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws.
Wellbeing's board of directors has also approved a grant of 210,000 restricted share units (RSUs) in aggregate to an affiliate of an arm’s length consultant. The RSUs will vest immediately on the date of issuance and each unit entitles the holder to receive one common share of the company in exchange.
Founded in 1997, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. It has produced 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points.
Contact the author at jon.hopkins@proactiveinvestors.com